Patents by Inventor Charles A. Nicolette

Charles A. Nicolette has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8513208
    Abstract: A method is provided for treating or preventing an undesired immune response in a patient, comprising: administering to said patient, cells that transiently express, and/or that are transfected with mRNA encoding, one or more polypeptides selected from the group consisting of an IL-4 receptor agonist, an IFN-? receptor antagonist, an IFN-? receptor antagonist, an IL-12 receptor antagonist, an IL-23 receptor antagonist, and a TNF antagonist. Preferably, the cells selectively accumulate in one or more secondary lymphoid tissues at or proximate to the site of the undesired immune response. Related compositions are provided. The methods and compositions are useful for the treatment or prevention of undesired immune responses including, but not limited to, transplant rejection, autoimmune disease, allergy and immune responses directed against therapeutic compositions.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: August 20, 2013
    Assignees: Argos Therapeutics, Inc., The Board of Trustees of the Leland Stanford Junior University
    Inventors: Charles A. Nicolette, C. Garrison Fathman, Remi Creusot
  • Patent number: 8029796
    Abstract: The present invention provides synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds, and immune effector cells raised in response to presentation of these epitopes. The invention further provides methods for inducing an immune response and administering immunotherapy to a subject by delivering the compositions of the invention.
    Type: Grant
    Filed: February 16, 2007
    Date of Patent: October 4, 2011
    Assignee: Genzyme Corporation
    Inventor: Charles A. Nicolette
  • Publication number: 20110081327
    Abstract: A method is provided for treating or preventing an undesired immune response in a patient, comprising: administering to said patient, cells that transiently express, and/or that are transfected with mRNA encoding, one or more polypeptides selected from the group consisting of an IL-4 receptor agonist, an IFN-? receptor antagonist, an IFN-? receptor antagonist, an IL-12 receptor antagonist, an IL-23 receptor antagonist, and a TNF antagonist. Preferably, the cells selectively accumulate in one or more secondary lymphoid tissues at or proximate to the site of the undesired immune response. Related compositions are provided. The methods and compositions are useful for the treatment or prevention of undesired immune responses including, but not limited to, transplant rejection, autoimmune disease, allergy and immune responses directed against therapeutic compositions.
    Type: Application
    Filed: February 27, 2009
    Publication date: April 7, 2011
    Inventors: Charles A. Nicolette, C. Garrison Fathman, Remi Creuset
  • Publication number: 20090148451
    Abstract: The present invention provides synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds, and immune effector cells raised in response to presentation of these epitopes. The invention further provides methods for inducing an immune response and administering immunotherapy to a subject by delivering the compositions of the invention.
    Type: Application
    Filed: February 16, 2007
    Publication date: June 11, 2009
    Inventor: Charles A. Nicolette
  • Patent number: 7202331
    Abstract: The present invention provides synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds, and immune effector cells raised in response to presentation of these epitopes. The invention further provides methods for inducing an immune response and administering immunotherapy to a subject by delivering the compositions of the invention.
    Type: Grant
    Filed: May 10, 2003
    Date of Patent: April 10, 2007
    Assignee: Genzyme Corporation
    Inventor: Charles A. Nicolette
  • Patent number: 6861408
    Abstract: The present invention provides synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds, and immune effector cells raised in response to presentation of these epitopes. The invention further provides methods for inducing an immune response and administering immunotherapy to a subject by delivering the compositions of the invention.
    Type: Grant
    Filed: May 21, 2001
    Date of Patent: March 1, 2005
    Assignee: Genzyme Corporation
    Inventor: Charles A. Nicolette
  • Publication number: 20040138135
    Abstract: The present invention provides synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds, and immune effector cells raised in response to presentation of these epitopes. The invention further provides methods for inducing an immune response and administering immunotherapy to a subject by delivering the compositions of the invention.
    Type: Application
    Filed: May 30, 2001
    Publication date: July 15, 2004
    Inventor: Charles A. Nicolette
  • Patent number: 6737062
    Abstract: The present invention provides synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds, and immune effector cells raised in response to presentation of these epitopes. The invention further provides methods for inducing an immune response and administering immunotherapy to a subject by delivering the compositions of the invention.
    Type: Grant
    Filed: May 30, 2001
    Date of Patent: May 18, 2004
    Assignee: Genzyme Corporation
    Inventor: Charles A. Nicolette
  • Publication number: 20040014697
    Abstract: Thus, this invention provides novel, synthetic polypeptide vaccines against human melanoma and methods for making these vaccines. Polynucleotides encoding these polypeptides are further provided herein.
    Type: Application
    Filed: August 1, 2001
    Publication date: January 22, 2004
    Inventor: Charles A. Nicolette
  • Publication number: 20030199673
    Abstract: The present invention provides synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds, and immune effector cells raised in response to presentation of these epitopes. The invention further provides methods for inducing an immune response and administering immunotherapy to a subject by delivering the compositions of the invention.
    Type: Application
    Filed: May 10, 2003
    Publication date: October 23, 2003
    Inventor: Charles A. Nicolette
  • Publication number: 20030175252
    Abstract: The present invention provides synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds, and immune effector cells raised in response to presentation of these epitopes. The invention further provides methods for inducing an immune response and administering immunotherapy to a subject by delivering the compositions of the invention.
    Type: Application
    Filed: May 30, 2001
    Publication date: September 18, 2003
    Inventor: Charles A. Nicolette
  • Publication number: 20030165517
    Abstract: The present invention provides synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds, and immune effect or cells raised in response to presentation of these epitopes. The invention further provides methods for inducing an immune response and administering immunotherapy to a subject by delivering the compositions of the invention.
    Type: Application
    Filed: October 29, 2002
    Publication date: September 4, 2003
    Inventors: Charles A. Nicolette, Bruce D. Walker
  • Publication number: 20030162720
    Abstract: The present invention provides synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds, and immune effector cells raised in response to presentation of these epitopes. The invention further provides methods for inducing an immune response and administering immunotherapy to a subject by delivering the compositions of the invention.
    Type: Application
    Filed: October 29, 2002
    Publication date: August 28, 2003
    Inventors: Charles A. Nicolette, Bruce D. Walker
  • Publication number: 20030147905
    Abstract: The present invention provides synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode the compounds, and immune effector cells raised in response to the presentation of these compounds. The invention further provides methods for inducing an immune response and administering immunotherapy to a subject by delivering the compounds of the invention.
    Type: Application
    Filed: January 8, 2003
    Publication date: August 7, 2003
    Inventor: Charles A. Nicolette
  • Publication number: 20030147866
    Abstract: The present invention provides methods and compositions for detecting, diagnosing, prognosing and monitoring the progress of BGP-related cancers and malignancies and kits for use in said methods. Further provided are methods for screening to identify agonists and antagonists of cancer antigens associated with BGP-related cancers and malignancies.
    Type: Application
    Filed: April 3, 2002
    Publication date: August 7, 2003
    Inventor: Charles A. Nicolette
  • Patent number: 6579970
    Abstract: The present invention provides synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds, and immune effector cells raised in response to presentation of these epitopes. The invention further provides methods for inducing an immune response and administering immunotherapy to a subject by delivering the compositions of the invention.
    Type: Grant
    Filed: March 19, 2001
    Date of Patent: June 17, 2003
    Assignee: Genzyme Corporation
    Inventor: Charles A. Nicolette
  • Patent number: 6528060
    Abstract: The present invention provides synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode the compounds, and immune effector cells raised in response to the presentation of these compounds. The invention further provides methods for inducing an immune response and administering immunotherapy to a subject by delivering the compounds of the invention.
    Type: Grant
    Filed: March 16, 2000
    Date of Patent: March 4, 2003
    Assignee: Genzyme Corporation
    Inventor: Charles A. Nicolette
  • Publication number: 20030013075
    Abstract: The present invention provides methods and compositions for detecting, diagnosing, prognosing and monitoring the progress of MART-1-related cancers and malignancies and kits for use in said methods. Further provided are methods for screening to identify agonists and antagonists of cancer antigens associated with MART-1-related cancers and malignancies.
    Type: Application
    Filed: January 31, 2002
    Publication date: January 16, 2003
    Inventor: Charles A. Nicolette
  • Publication number: 20020197243
    Abstract: The present invention provides methods and compositions for detecting, diagnosing, prognosing and monitoring the progress of p53BP2-related cancers and malignancies and kits for use in said methods. Further provided are methods for screening to identify agonists and antagonists of cancer antigens associated with p53BP2-related cancers and malignancies.
    Type: Application
    Filed: April 1, 2002
    Publication date: December 26, 2002
    Inventor: Charles A. Nicolette
  • Publication number: 20020187494
    Abstract: The present invention provides methods and compositions for detecting, diagnosing, prognosing and monitoring the progress of PAR-3-related cancers and malignancies and kits for use in said methods. Further provided are methods for screening to identify agonists and antagonists of cancer antigens associated with PAR-3-related cancers and malignancies.
    Type: Application
    Filed: February 19, 2002
    Publication date: December 12, 2002
    Inventor: Charles A. Nicolette